3053 related articles for article (PubMed ID: 7927369)
41. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
Heo DS; Whiteside TL; Kanbour A; Herberman RB
J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
[TBL] [Abstract][Full Text] [Related]
42. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
43. In vitro generation of immune effector cells from tumor-associated lymphocytes of human gastric cancer.
Kim HJ; Heo DS; Suh CI; Kim HT; Bang YJ; Kim NK
Anticancer Res; 1995; 15(4):1247-55. PubMed ID: 7654004
[TBL] [Abstract][Full Text] [Related]
44. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
45. Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy.
Olencki T; Finke J; Tubbs R; Tuason L; Greene T; McLain D; Swanson SJ; Herzog P; Stanley J; Edinger M; Budd GT; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):69-80. PubMed ID: 8859726
[TBL] [Abstract][Full Text] [Related]
46. Low molecular weight B-cell growth factor and recombinant interleukin-2 are together able to generate cytotoxic T lymphocytes with LAK activity from the bone marrow cells of children with acute lymphoblastic leukemia.
Zhou MX; Findley HW; Ragab AH
Blood; 1989 Sep; 74(4):1355-9. PubMed ID: 2788465
[TBL] [Abstract][Full Text] [Related]
47. [Analysis of growth, phenotype and cytotoxic activity of tumor infiltrating lymphocytes expanded in vitro with interleukin-2 and interleukin-4: preliminary results].
Manna R; Cristiano G; Severino Martin L; Emerentienne Sambakay C; Liang LI; Crucitti F; Iudicone P; Salgarello G; Gambassi G; Quintiliani L
Ann Ital Med Int; 1992; 7(1):19-25. PubMed ID: 1388039
[TBL] [Abstract][Full Text] [Related]
48. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
[TBL] [Abstract][Full Text] [Related]
49. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
50. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
51. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone.
Hayakawa K; Salmeron MA; Kornbluth J; Bucana C; Itoh K
J Immunol; 1991 Apr; 146(7):2453-60. PubMed ID: 1900882
[TBL] [Abstract][Full Text] [Related]
52. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
[TBL] [Abstract][Full Text] [Related]
53. Phenotypical and functional differences of tumor-infiltrating lymphocytes from human colorectal cancers induced by costimulation with rIL-2 and rIL-4 in vitro.
Keller H; Wimmenauer S; Rahner S; Von Kleist S; Farthmann EH
Anticancer Res; 1996; 16(6B):3565-70. PubMed ID: 9042222
[TBL] [Abstract][Full Text] [Related]
54. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
55. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
Gervois N; Heuze F; Diez E; Jotereau F
Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
[TBL] [Abstract][Full Text] [Related]
56. Selection of cytotoxic T lymphocytes against autologous human melanoma from lymph nodes with metastatic melanoma using repeated in vitro sensitization.
Leong SP; Granberry ME; Zhou YM; Wang TF; Grogan TM
Clin Exp Metastasis; 1991; 9(3):301-17. PubMed ID: 2060186
[No Abstract] [Full Text] [Related]
57. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
Yang SC; Fry KD; Grimm EA; Roth JA
J Immunother (1991); 1991 Oct; 10(5):326-35. PubMed ID: 1790140
[TBL] [Abstract][Full Text] [Related]
58. Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.
Cozzolino F; Torcia M; Carossino AM; Giordani R; Selli C; Talini G; Reali E; Novelli A; Pistoia V; Ferrarini M
J Exp Med; 1987 Aug; 166(2):303-18. PubMed ID: 2955070
[TBL] [Abstract][Full Text] [Related]
59. Human autologous tumor-specific T cells in malignant melanoma.
Platsoucas CD
Cancer Metastasis Rev; 1991 Jun; 10(2):151-76. PubMed ID: 1873855
[TBL] [Abstract][Full Text] [Related]
60. Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer.
Vlasveld LT; van de Wiel-van Kemenade E; de Boer AJ; Sein JJ; Gallee MP; Krediet RT; Mellief CJ; Rankin EM; Hekman A; Figdor CG
Cancer Immunol Immunother; 1993; 36(3):210-3. PubMed ID: 8439983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
